JonesResearch downgraded Monopar Therapeutics (MNPR) to Hold from Buy without a price target following the Q4 report. The firm remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback